


Respiratory Pathogens Data Jul 02- Oct 21 2017

Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV / Rhino	Meta pneumo	Adeno	All Corona	Bocca	Myco plasma	Chla mydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/M %FLU	EIA %FLU
OCT 14	0	0	0	0	3	24	59	1	2	2	2	0	1	94	0	364	0.0	n/a	n/a	1.6
OCT 8	0	0	1	0	6	33	91	3	0	2	0	2	0	138	1	333	0.3	2.5	0.9	2.8
Oct 01	0	0	0	0	1	18	73	1	3	0	2	1	0	99	0	340	0.0	2.7	1.8	1.6
SEPT 24	0	0	0	0	1	24	79	0	3	3	3	0	0	113	0	286	0.0	2.0	1.0	1.6
SEPT 17	0	0	0	0	3	9	93	1	4	0	3	1	0	114	0	314	0.0	1.6	1.2	3.5
SEP 9	0	0	0	0	0	18	94	3	2	2	0	0	0	119	0	359	0.0	1.6	1.3	1.8
SEP 2	0	0	1	0	0	12	49	0	5	1	1	1	0	70	1	234	0.4	1.7	1.5	2.7
AUG 27	0	0	2	0	1	14	62	1	4	1	2	0	0	87	2	252	0.8	1.8	1.1	1.6
AUG 20	0	1	0	1	0	11	28	3	1	3	1	1	1	51	2	215	0.9	1.9	0.9	4.2
AUG 13	0	0	2	0	0	8	32	2	3	2	3	0	1	53	2	196	1.0	1.7	0.8	3.6
AUG 6	0	0	0	0	1	10	30	1	1	1	1	1	1	47	0	211	0.0	2.3	1.0	0.0
JULY 30	0	0	0	0	0	7	32	4	0	1	0	0	0	44	0	214	0.0	2.2	1.2	0.0
JULY 23	0	0	0	0	0	9	17	1	2	2	0	0	0	31	0	197	0.0	2.4	1.4	0.0
JULY 16	0	0	0	2	0	5	21	4	2	0	0	1	0	35	0	187	1.1	2.1	0.6	0.0
JULY 9	0	0	0	0	0	12	37	6	2	1	2	1	0	61	0	222	0.0	2.4	0.9	6.7
JULY 2	0	0	1	1	0	16	34	4	3	1	1	1	0	62	0	224	0.9	2.4	0.4	1.8


Flu PCR
% Rate

ACL RESP. PANEL - POSITIVE RATE 25.8%




ACL Influenza PCR POS 0.0%

POS FLU
Total




ACL FLUAG EIA POS 1.6%

Total
POS EIA




CDC Oct 21, 2017 Positivity rate 2.5% - Flu A – 69% (2009 H1N1 -4% , seasonal H3 -88%) Flu B – 31%

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 2, 2016 – October 21, 2017




Week Ending Oct 21, 2017 - Week 42




*This map indicates geographic spread and does not measure the severity of influenza activity.


The most prevalent targets as **Oct 21st** are; **Enterovirus, HSV2** (positivity rate 18.4%)





The most prevalent targets as **Oct 21st** are; **Salmonella** and **Giardia**



The most prevalent target as Oct 21st is; Low level of NORO GI virus





Neuraminidase Inhibitors Resistance - **no new update by CDC since May 2017**

Per CDC website	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	324	0	324	0	324	0
Influenza A (H3N2)	2305	0	2305	0	1279	0
Influenza B	829	0	829	0	829	0

Update Aug- 2017 PAHO/CDC

Target	Source	Period	CDC	US % POS	ACL 2017
Locally acquired	US (endemic)	Jan 2017-Aug 2017	0	0.00	
Zika virus US import	US (travelers)	Jan 2017-Aug 2017	185	0.06	4
Zika virus US territory.	US (local)Puerto Rico	Jan 2017-Aug 2017	553	0.15	0
Dengue US import	US (travelers)	07/31/17	62	0.02	3
Dengue US territory	US (local)Puerto Rico9	07/31/17	9	0.00	0
Chikungunya US import	US (travelers)	Jan 2017-Aug 2017	20	0.01	1
Chikungunya US territory	US (local)Puerto Rico	Jan 2017-Aug 2017	15	0.00	0